EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blood–Brain Barrier (BBB)-Penetrable Androgen Receptor (AR) Degrader as a Potential Therapeutic Agent for Glioblastoma

Xiaotong Zhao, Yaxin Li, William R Martin iD, Fatma Salem, Ruchitha Korem, Soha Bolbol, Garrett Worden, Maheen Sajid, Alia Al-Rousan, Blake Wilt, Wenjing Zhang, Lyubomyr Turchyn und 5 weitere

ACS Pharmacology & Translational Science · 08.05.2026 · 9 (5) · 1164-1176

DOI: 10.1021/acsptsci.5c00821 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 06.04.2026. Verfasst von Xiaotong Zhao und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 21…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Neurological Disorders and Stroke, Center for Gene Regulation in Health and Disease, Cleveland State University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

BBBandrogen receptorglioblastomaprotein degradationsex disparity

Autor:innen und Institutionen

  • Department of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
  • Genomic Medicine Institute, Cleveland Clinic Genome Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.
  • Animal Research Facility, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
  • Department of Biochemistry, School of Medicine, Case Western Reserve University, 10900 Euclid Ave., Cleveland, Ohio 44106, United States.
  • Department of Mechanic Engineering, College of Engineering, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
  • Department of Cancer Sciences, Cleveland Clinic Research, Cleveland, Ohio 44195, United States.

ORCID-Profile: William R Martin, Liqun Ning, Bin Su

Förderung

  • National Institute of Neurological Disorders and Stroke
  • Center for Gene Regulation in Health and Disease, Cleveland State University

Zitieren

APA

Zhao, X., Li, Y., Martin, W. R., Salem, F., Korem, R., Bolbol, S., Worden, G., Sajid, M., Al-Rousan, A., Wilt, B., Zhang, W., Turchyn, L., Hubert, C., Ning, L., Lathia, J. D., Zhou, A., & Su, B. (2026). Blood–Brain Barrier (BBB)-Penetrable Androgen Receptor (AR) Degrader as a Potential Therapeutic Agent for Glioblastoma. ACS Pharmacology & Translational Science, 9(5), 1164-1176. https://doi.org/10.1021/acsptsci.5c00821

Vancouver

Zhao X, Li Y, Martin WR, Salem F, Korem R, Bolbol S, et al. Blood–Brain Barrier (BBB)-Penetrable Androgen Receptor (AR) Degrader as a Potential Therapeutic Agent for Glioblastoma. ACS Pharmacology & Translational Science. 2026;9(5):1164-1176. doi:10.1021/acsptsci.5c00821

BibTeX
@article{Zhao2026,
  author = {Zhao, Xiaotong and Li, Yaxin and Martin, William R and Salem, Fatma and Korem, Ruchitha and Bolbol, Soha and Worden, Garrett and Sajid, Maheen and Al-Rousan, Alia and Wilt, Blake and Zhang, Wenjing and Turchyn, Lyubomyr and Hubert, Christopher and Ning, Liqun and Lathia, Justin D and Zhou, Aimin and Su, Bin},
  title = {Blood–Brain Barrier (BBB)-Penetrable Androgen Receptor (AR) Degrader as a Potential Therapeutic Agent for Glioblastoma},
  journal = {ACS Pharmacology & Translational Science},
  year = {2026},
  volume = {9},
  number = {5},
  pages = {1164--1176},
  doi = {10.1021/acsptsci.5c00821}
}
Kostenlos starten →